Briacell Therapeutics (CVE:BCT) Hits New 12-Month Low at $0.04

Briacell Therapeutics Corp (CVE:BCT)’s share price reached a new 52-week low on Tuesday . The stock traded as low as C$0.04 and last traded at C$0.04, with a volume of 219000 shares changing hands. The stock had previously closed at C$0.04.

The stock has a market capitalization of $8.66 million and a price-to-earnings ratio of -1.06. The company has a debt-to-equity ratio of 48.40, a quick ratio of 0.14 and a current ratio of 0.15. The business has a 50-day moving average of C$0.04 and a 200-day moving average of C$0.07.

Briacell Therapeutics (CVE:BCT) last issued its quarterly earnings results on Tuesday, October 22nd. The company reported C($0.03) earnings per share (EPS) for the quarter.

Briacell Therapeutics Company Profile (CVE:BCT)

BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, develops personalized treatments for cancer. Its lead product candidate is Bria-IMT, a clinical trial in combination with pembrolizumab (KEYTRUDA; manufactured by Merck & Co, Inc) for use in patients with breast cancer.

Featured Story: What is the Book Value of a Share?

Receive News & Ratings for Briacell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Briacell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.